New Guidelines Launched to Improve Child Health Research Reviews

Medical researchers now have better tools to review evidence about treatments for children and teenagers. The PRISMA Group has launched new guidelines specifically designed for paediatric systematic reviews.

PRISMA-C 2026 fills gaps left by existing adult-focused research protocols. The extension includes seven reporting items, four abstract items, and ten items where developmental considerations apply.

Why Children Need Different Standards

Large clinical trials involving children remain uncommon. But evidence reviews continue to provide vital information for paediatric medicine, according to research published in the British Medical Journal.

Standard PRISMA guidelines from 2009 and PRISMA-P from 2015 don’t fully address child-specific factors. These include different interventions, outcome measures, and search strategies needed for young patients.

The new extension applies to all paediatric systematic reviews, whether they include statistical analysis or not. Researchers developed it through a collaborative process involving multiple medical disciplines.

Building Better Evidence

Children’s bodies change as they grow. This creates unique challenges when reviewing medical evidence across different age groups.

The PRISMA-C extension addresses these developmental complexities. It also tackles ethical considerations specific to research involving minors.

Medical professionals can now apply more rigorous standards when synthesising evidence about child health interventions. This should lead to more reliable conclusions about what treatments work best for young patients.

From Research to Practice

The guidelines emerged from recognition that children aren’t just small adults. Their medical needs require specialised approaches to evidence review.

Systematic reviews play a vital role in paediatric medicine because large randomised trials in children are rare. The new standards aim to make these reviews more transparent and useful for clinical decision-making.

Key Takeaways

• PRISMA-C 2026 provides the first child-specific standards for medical evidence reviews
• The guidelines include 21 items covering reporting, abstracts, and developmental considerations
• Large paediatric clinical trials remain uncommon, making systematic reviews vital for child healthcare decisions

What This Means for Kent Residents

Kent families can expect more reliable evidence behind their children’s medical treatments as local NHS services adopt these improved research standards. The NHS Kent and Medway Integrated Care Board will use PRISMA-C 2026 when evaluating paediatric interventions for local clinical guidelines and commissioning decisions. Parents should continue consulting their GP or NHS 111 for any child health concerns, knowing that treatment recommendations increasingly rely on higher-quality evidence reviews designed specifically for young patients.